Lake Street analyst Thomas Flaten raised the firm’s price target on OncoCyte (OCX) to $8 from $5 and keeps a Buy rating on the shares after the company announced CMS “substantially” increased the reimbursed rate for GraftAssureCore to $2,753. The firm believes this “augurs well” for future GraftAssureDx pricing, so it has raised estimates, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCX:
- OncoCyte Corp’s Earnings Call: Optimism Amid Challenges
- OncoCyte’s Strategic Initiatives and Financial Management Drive Buy Rating
- OncoCyte Corp Reports Revenue Growth Amid Losses
- OCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- OncoCyte provides update on progress toward initiating clinical trial